Posted by Michael Wonder on 15 Jun 2019
Asthma and Allergy Foundation of America elevates patient voice in ICER review of new peanut allergy treatments
14 June 2019 - On June 11 in Oakland, CA the Institute for Clinical and Economic Review and its California Technology Assessment Forum met to assess the clinical effectiveness and value of treatments for peanut allergy.
The review examined two new technologies to induce immune tolerance — Viaskin Peanut (DBV Technologies) and AR101 (Aimmune Therapeutics) — as well as non-commercialised oral immunotherapy.
ICER invited the Asthma and Allergy Foundation of America (AAFA) to share AAFA’s recent research results that describe the burden of food allergies on patients and caregivers. ICER’s final evidence report and meeting summary will be released on 11 July.
